Benefit of adjuvant radiation therapy for localized prostate cancer with a positive surgical margin

被引:81
|
作者
Leibovich, BC [1 ]
Engen, DE [1 ]
Patterson, DE [1 ]
Pisansky, TM [1 ]
Alexander, EE [1 ]
Blute, ML [1 ]
Bergstralh, EJ [1 ]
Zincke, H [1 ]
机构
[1] Mayo Clin & Mayo Fdn, Dept Urol, Biostat Sect, Div Radiat Oncol, Rochester, MN 55905 USA
来源
JOURNAL OF UROLOGY | 2000年 / 163卷 / 04期
关键词
combined modality therapy; prostatic neoplasms; prostatectomy; prostate; radiotherapy; adjuvant;
D O I
10.1016/S0022-5347(05)67717-8
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: Positive surgical margins are common after radical prostatectomy, and the role of adjuvant therapy in such cases is controversial. We determined the benefit of postoperative external beam radiation therapy in patients with margin positive prostate cancer with respect to biochemical progression or cancer recurrence. To decrease confounding factors that may affect the likelihood of biochemical progression our study was limited to men with organ confined cancer and a single positive margin. Materials and Methods: We retrospectively evaluated the records of a nested matched cohort of 76 patients with pathological stage T2N0 prostate cancer and a single positive margin who underwent adjuvant radiation therapy within 3 months of radical prostatectomy. There was a positive margin at the prostatic apex in 35 cases, prostatic base in 18, posterior prostate in 11, urethra in 7, and prostatic apex and urethra in 5. These patients were matched 1:1 with 76 controls who did not receive adjuvant radiation therapy. Neither group received androgen deprivation therapy. Patients and controls were matched exactly for the margin positive site, age at surgery, preoperative serum prostate specific antigen, Gleason score and DNA ploidy. Biochemical relapse was defined as posttreatment PSA greater than 0.2 ng./ml. Results: Overall there was significant estimated improvement plus or minus standard error in 5-year clinical and biochemical progression-free survival in 88% +/- 5% versus 59% +/- 11% of patients treated with adjuvant radiation therapy versus no radiation therapy (p = 0.005). No patient who received radiation therapy had local or distant recurrence, while 16% of controls had recurrence (p = 0.015). When stratified by site of margin positivity, the 5-year estimated clinical and biochemical progression-free rate in 18 cases and controls with a positive base margin was 95% +/- 15% and 65% +/- 13% respectively (p = 0.02). The rate in 35 cases and cases with a positive apex margin was 95% +/- 5% and 64% +/- 15%, respectively (p = 0.07). Limited sample size precluded analysis of the other sites. Conclusions: Patients with localized prostate cancer and a singe positive surgical margin appear to have a lower rate of biochemical relapse at 5 years when adjuvant radiation therapy is administered. Defmitive evidence of the beneficial effect of adjuvant radiation therapy for patients with involved surgical margins awaits conclusion of randomized clinical trials.
引用
收藏
页码:1178 / 1182
页数:5
相关论文
共 50 条
  • [41] Organ-limited prostate cancer with positive resection margins. Importance of adjuvant radiation therapy
    Porres, D.
    Pfister, D.
    Brehmer, B.
    Heidenreich, A.
    UROLOGE, 2012, 51 (09): : 1246 - 1252
  • [42] Radiation therapy for prostate cancer after prostatectomy: adjuvant or salvage?
    Patel, Amit R.
    Stephenson, Andrew J.
    NATURE REVIEWS UROLOGY, 2011, 8 (07) : 385 - 392
  • [43] Pretreatment Predictors of Receiving Adjuvant Radiation Therapy for Prostate Cancer
    Zaorsky, N. G.
    Handorf, E.
    Horwitz, E. M.
    Hallman, M. A.
    Smaldone, M. C.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 96 (02): : E280 - E280
  • [44] Radiation therapy for prostate cancer after prostatectomy: adjuvant or salvage?
    Amit R. Patel
    Andrew J. Stephenson
    Nature Reviews Urology, 2011, 8 : 385 - 392
  • [45] Stereotactic body radiation therapy for clinically localized prostate cancer
    Vorobyov, N. A.
    Martynova, N. I.
    Mikhailov, A. V.
    Gutsalo, Yu. V.
    Kubasov, A. V.
    ONKOUROLOGIYA, 2018, 14 (02): : 122 - 129
  • [46] Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer
    Voog, Justin C.
    Smith, Matthew R.
    Efstathiou, Jason A.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2016, 315 (10): : 1054 - 1055
  • [47] Stereotactic radiation therapy of localized prostate cancer using cyberknife
    Choi, C.
    Cho, C.
    Kim, G.
    Park, K.
    Jo, M.
    Lee, C.
    Yoo, S.
    Kim, M.
    Yang, K.
    Yoo, H.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 69 (03): : S375 - S375
  • [48] The Current Trend of Radiation Therapy for Patients with Localized Prostate Cancer
    Numakura, Kazuyuki
    Kobayashi, Mizuki
    Muto, Yumina
    Sato, Hiromi
    Sekine, Yuya
    Sobu, Ryuta
    Aoyama, Yu
    Takahashi, Yoshiko
    Okada, Syuhei
    Sasagawa, Hajime
    Narita, Shintaro
    Kumagai, Satoshi
    Wada, Yuki
    Mori, Naoko
    Habuchi, Tomonori
    CURRENT ONCOLOGY, 2023, 30 (09) : 8092 - 8110
  • [49] Overview of Radiation Therapy in the Management of Localized and Metastatic Prostate Cancer
    Mattes, Malcolm D.
    CURRENT UROLOGY REPORTS, 2024, 25 (08) : 181 - 192
  • [50] Good tolerability of hypofractionated radiation therapy for localized prostate cancer
    Navarro, I.
    Correa, R.
    Otero, A.
    Roman, A.
    Zapata, I.
    Fernandez, A.
    Prieto, P.
    Segado, S.
    Jodar, C.
    Garrido, C.
    Medina, J. A.
    Gomez, J.
    RADIOTHERAPY AND ONCOLOGY, 2019, 133 : S853 - S854